ANAPTYSBIO INC (ANAB:NASDAQ)
$66.9 -0.99 (-1.4582%)
Analysed ANAPTYSBIO INC (ANAB:NASDAQ) News Sources
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings
05-04-2026
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
27-03-2026
yahoo.com
Sector Update: Health Care Stocks Retreat Friday Afternoon
27-03-2026
yahoo.com
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares
27-03-2026
yahoo.com
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
27-03-2026
yahoo.com
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
27-03-2026
yahoo.com
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
27-03-2026
yahoo.com
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
16-03-2026
yahoo.com
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline
12-03-2026
marketbeat.com
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible
11-03-2026
marketbeat.com
What is the current price of ANAPTYSBIO INC (ANAB:NASDAQ)?
The current price of ANAPTYSBIO INC (ANAB:NASDAQ) is $66.9.
ANAPTYSBIO INC (ANAB:NASDAQ) absolute price change since previous trading day?
The absolute price change of ANAPTYSBIO INC (ANAB:NASDAQ) since the previous trading day is $-0.99.
ANAPTYSBIO INC (ANAB:NASDAQ) percentage price change since previous trading day?
The percentage price change of ANAPTYSBIO INC (ANAB:NASDAQ) since the previous trading day is -1.4582%.
What is the most recent average sentiment score for ANAPTYSBIO INC (ANAB:NASDAQ)?
The most recent average sentiment score for ANAPTYSBIO INC (ANAB:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for ANAPTYSBIO INC (ANAB:NASDAQ)?
The most recent sentiment for ANAPTYSBIO INC (ANAB:NASDAQ) is .
SEC-8K** Filing Available For ANAPTYSBIO INC (ANAB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.